Investment Counselors of Maryland’s ANI Pharmaceuticals ANIP Stock Holding History

Investment Counselors of Maryland’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$13.4M	Buy	383,696 +31,682	+9%	+$1.08M	0.31%	106
2021 Q1	$12.7M	Buy	352,014 +12,162	+4%	+$381K	0.33%	102
2020 Q4	$9.87M	Buy	339,852 +17,877	+6%	+$512K	0.32%	105
2020 Q3	$9.08M	Buy	321,975 +42,609	+15%	+$1.27M	0.41%	101
2020 Q2	$9.04M	Sell	279,366 -5,071	-2%	-$182K	0.47%	98
2020 Q1	$11.6M	Buy	284,437 +103	+0%	+$5.48K	0.75%	79
2019 Q4	$17.5M	Buy	284,334 +4,974	+2%	+$329K	0.75%	83
2019 Q3	$20.4M	Sell	279,360 -619	-0.2%	-$46.3K	0.94%	58
2019 Q2	$23M	Buy	279,979 +3,100	+1%	+$220K	1.07%	31
2019 Q1	$19.5M	Buy	276,879 +69,579	+34%	+$4.09M	0.95%	58
2018 Q4	$9.33M	Buy	207,300 +183,515	+772%	+$9.62M	0.54%	95
2018 Q3	$1.34M	Buy	+23,785	New	+$1.46M	0.06%	134
2018 Q1	–	Sell	-61,412	Closed	-$3.96M	–	194
2017 Q4	$3.96M	Hold	61,412	–	–	0.2%	106
2017 Q3	$3.22M	Buy	+61,412	New	+$2.93M	0.16%	108

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Investment Counselors of Maryland's ANIP Position: Q2 2021 in Review

Investment Counselors of Maryland increased its ANI Pharmaceuticals (ANIP) stake by 9% in Q2 2021, buying an estimated $1.08M and bringing the position to 383,696 shares worth $13.4M. The position accounts for 0.31% of the portfolio, ranked #106.

Investment Counselors of Maryland first reported a position in ANIP in Q3 2017 and has held it in 14 quarters since. The position peaked at $23M in Q2 2019. 116 funds tracked by Wall St. Rank hold ANIP as of Q2 2021.

Investment Counselors of Maryland held 383,696 shares of ANI Pharmaceuticals worth $13.4M as of Q2 2021.
Investment Counselors of Maryland bought 31,682 ANI Pharmaceuticals shares in Q2 2021, an estimated $1.08M.
ANI Pharmaceuticals made up 0.31% of Investment Counselors of Maryland's portfolio in Q2 2021, its #106 holding.
Investment Counselors of Maryland first reported a position in ANI Pharmaceuticals in Q3 2017 and has held it in 14 quarters since.
Investment Counselors of Maryland's ANI Pharmaceuticals position peaked at $23M in Q2 2019.
116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2021.

Based on Investment Counselors of Maryland's 13F filing for Q2 2021, filed 16 Jul 2021.